NasdaqGM - Delayed Quote USD

UroGen Pharma Ltd. (URGN)

Compare
12.25 +0.10 (+0.82%)
At close: October 29 at 4:00 PM EDT
Loading Chart for URGN
DELL
  • Previous Close 12.15
  • Open 12.10
  • Bid 12.23 x 100
  • Ask 12.27 x 100
  • Day's Range 12.03 - 12.45
  • 52 Week Range 10.60 - 20.70
  • Volume 418,979
  • Avg. Volume 578,328
  • Market Cap (intraday) 515.898M
  • Beta (5Y Monthly) 1.12
  • PE Ratio (TTM) --
  • EPS (TTM) -3.09
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 40.75

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpr?parate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

www.urogen.com

203

Full Time Employees

December 31

Fiscal Year Ends

Recent News: URGN

View More

Performance Overview: URGN

Trailing total returns as of 10/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

URGN
18.33%
S&P 500
22.29%

1-Year Return

URGN
10.76%
S&P 500
41.67%

3-Year Return

URGN
24.66%
S&P 500
26.90%

5-Year Return

URGN
45.72%
S&P 500
91.91%

Compare To: URGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: URGN

View More

Valuation Measures

Annual
As of 10/29/2024
  • Market Cap

    515.90M

  • Enterprise Value

    373.06M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.00

  • Price/Book (mrq)

    17.02

  • Enterprise Value/Revenue

    4.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -133.61%

  • Return on Assets (ttm)

    -26.24%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    85.01M

  • Net Income Avi to Common (ttm)

    -113.58M

  • Diluted EPS (ttm)

    -3.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    241.08M

  • Total Debt/Equity (mrq)

    326.69%

  • Levered Free Cash Flow (ttm)

    -40.72M

Research Analysis: URGN

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 21.85M
Earnings -33.4M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

22.00
40.75 Average
12.25 Current
64.00 High
 

Company Insights: URGN

People Also Watch